Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

por Awada, A, Hendlisz, A, Gil, T, Bartholomeus, S, Mano, M, de Valeriola, D, Strumberg, D, Brendel, E, Haase, C G, Schwartz, B, Piccart, M
Publicado 2005

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

por de Azambuja, E, Cardoso, F, de Castro, G, Colozza, M, Mano, M S, Durbecq, V, Sotiriou, C, Larsimont, D, Piccart-Gebhart, M J, Paesmans, M
Publicado 2007

Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2− locally advanced breast cancer

por Petry, V., Gagliato, D.M., Leal, A.I.C., Arai, R.J., Longo, E., Andrade, F., Ricci, M.D., Piato, J.R., Barroso-Sousa, R., Hoff, P.M., Mano, M.S.
Publicado 2015

Mastectomy rates are decreasing in the era of service screening: a population-based study in Italy (1997–2001)

por Zorzi, M, Puliti, D, Vettorazzi, M, De Lisi, V, Falcini, F, Federico, M, Ferretti, S, Moffa, I F, Mangone, L, Mano, M P, Naldoni, C, Ponti, A, Traina, A, Tumino, R, Paci, E
Publicado 2006